tiprankstipranks
Atyr Pharma Inc. (ATYR)
NASDAQ:ATYR
US Market
ATYR
aTyr Pharma
RESEARCH TOOLSreports
Want to see ATYR full AI Analyst Report?

aTyr Pharma (ATYR) Stock News & Sentiment

2,835 Followers
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
Premium
Ratings
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
9d ago
ATYR
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
Premium
Ratings
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
9d ago
ATYR
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
Premium
Company Announcements
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
10d ago
8K
ATYR
ATYR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ATYR Upcoming Earnings Report: What to Expect?
10d ago
ATYR
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
Premium
Company Announcements
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
3M ago
ATYR
aTyr Pharma Receives Nasdaq Deficiency Notice
Premium
Company Announcements
aTyr Pharma Receives Nasdaq Deficiency Notice
6M ago
8K
ATYR
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
Premium
Market News
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
6M ago
ATYR
More ATYR News >

ATYR News on the Web

aTyr Pharma upgraded to Buy from Hold at Freedom Broker
TipRanks News
Bullish
RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)
TipRanks News
Neutral
Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)
TipRanks News
Neutral
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
TipRanks News
Neutral
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
TipRanks News
Bullish
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
TipRanks News
Bullish
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
TipRanks News
Neutral
Piper Sandler Sticks to Their Buy Rating for aTyr Pharma (ATYR)
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
ATYR
Sector Average
Media Buzz
This Week6 articles
Weekly Average2.25 articles
News Sentiment
This Week99%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ATYR’s Media Buzz Sentiment?
6 articles about ATYR were published this week. In an average week, 2.25 articles are published.
    What is ATYR’s weekly average amount of articles?
    In an average week, 2.25 articles about ATYR are published.
      What is ATYR’s News Sentiment?
      99% of articles about ATYR were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week